DrugPatentWatch Database Preview
Details for Patent: 5,763,476
» See Plans and Pricing
Which drugs does patent 5,763,476 protect, and when does it expire?
Patent 5,763,476 protects SAPHRIS and is included in one NDA.
Protection for SAPHRIS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-five patent family members in twenty-one countries.
Summary for Patent: 5,763,476
Title: | Sublingual or buccal pharmaceutical composition |
Abstract: | The invention relates to a sublingual or buccal pharmaceutical composition comprising trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino-[4 ,5-c]pyrrole or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable auxiliaries suitable for use in sublingual or buccal compositions, and the use thereof for the manufacture of a sublingual or buccal pharmaceutical composition for the treatment of mental disorders, such as psychosis and schizophrenia. |
Inventor(s): | Delbressine; Leonardus Petrus Carla (Nijmegen, NL), Wieringa; Johannes Hubertus (Heesch, NL) |
Assignee: | Akzo Noble N.V. (Arnhem, NL) |
Application Number: | 08/693,064 |
Patent Claim Types: see list of patent claims | Composition; Compound; Use; Process; Formulation; |
Drugs Protected by US Patent 5,763,476
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan | SAPHRIS | asenapine maleate | TABLET;SUBLINGUAL | 022117-003 | Mar 12, 2015 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
Allergan | SAPHRIS | asenapine maleate | TABLET;SUBLINGUAL | 022117-001 | Aug 13, 2009 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
Allergan | SAPHRIS | asenapine maleate | TABLET;SUBLINGUAL | 022117-002 | Aug 13, 2009 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 5,763,476
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
94200521 | Mar 02, 1994 |
PCT Information | |||
PCT Filed | March 01, 1995 | PCT Application Number: | PCT/EP95/00765 |
PCT Publication Date: | September 08, 1995 | PCT Publication Number: | WO95/23600 |
International Family Members for US Patent 5,763,476
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 167057 | Start Trial | |||
Australia | 1947895 | Start Trial | |||
Australia | 692530 | Start Trial | |||
Brazil | 1100625 | Start Trial | |||
Brazil | 9506924 | Start Trial | |||
Canada | 2182981 | Start Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |